GSK is focused on maximizing patient survival through transformational medicines. GSK’s pipeline is focused on immuno-oncology, cell therapy, cancer epigenetics and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination. Please visit our virtual booth for more information.
1250 South Collegeville Rd.
Collegeville, PA 19426
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.
Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have two commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases including cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.
Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol-Myers Squibb company and Juno Therapeutics, a Bristol-Myers Squibb company.
At Janssen, helping patients overcome the challenges they face is our mission and privilege. We focus our efforts on discovering first of a kind medicines for cancers where there are limited treatment options and strive to make cancer a manageable, even curable condition.
Janssen Pharmaceutica NV
2340 Beerse Belgium
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.
- full company name: Amgen Europe GmbH
- mailing address: Suurstoffi 22, P.O. Box 94, CH-6343 Rotkreuz, Switzerland
- telephone: +41 41 369 03 00; fax: NA, email: NA and URL: www.amgen.com
Neopharm Israel is dedicated to the marketing and sales of premium ethical prescription products – pharmaceuticals, orphan drugs and biologic drugs.
Neopharm Israel is the exclusive representative and partner of leading multinational bio-pharma and consumer healthcare brands including Alexion, Karyopharm, Fresenius and many more.
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases.
The company is focusing on the development of the lead candidate melflufen, a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells.
Melflufen is in development as a new treatment for multiple myeloma and is currently tested in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study.
Oncopeptides’ headquarters is in Stockholm, Sweden, and the company is listed in the Mid Cap segment on Nasdaq Stockholm.
Binding Site developed Freelite and, since 2001, is manufacturing and commercialising this assay which is the gold standard for Free Light Chains quantification (FLC).
FLC became essential bio-markers for the management of Multiple Myeloma, Smoldering Multiple Myeloma, AL amyloidosis and Monoclonal Gammopathies of Undetermined Significance. that The International Myeloma Working Group updated over time diagnosis and monitoring criteria including FLC parameters based on Freelite values.
Expert for specific proteins, Binding Site is able to give the unique attention required and collaborates with biologists and clinicians your team for an optimal use and interpretation of in-vitro tests in plasma cell disorders management.
The Binding Site France – 32 rue des platanes CS30026 – 38522 Saint Egrève cedex – Tel +33 438 02 19 19 – firstname.lastname@example.org– www.bindingsite.com
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D. Genentech, in the United States, is a wholly owned member of the Roche Group
The Video Journal of Hematological Oncology (VJHemOnc) is an independent, open-access video journal, dedicated to providing trusted and up to date information to the healthcare professional community through innovative digital media – including video, podcasts, editorial features and more. We provide rapid publishing of expert opinion from global medical congresses in order to improve the awareness and understanding of hematological cancers. Visit www.VJHemOnc.com to get the latest updates in multiple myeloma.
Multiple Myeloma Hub
Guided by an international Steering Committee of world-leading experts in multiple myeloma (MM), the MM Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in MM. Our aim is to enhance knowledge in MM, through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.
The MM Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
Our website is available at the following address: www.multiplemyelomahub.com.
Our social media accounts are listed below:
- Twitter: @MM_Hub
- Facebook: @multiplemyelomahub
- LinkedIn: multiple-myeloma-hub
- YouTube: multiplemyelomahub